Trellus Health plc (LSE:TRLS) is moving towards administration after its board concluded that the AIM-listed digital healthcare company no longer has sufficient funding to continue operating as a going concern.
The company has filed a notice of intention to appoint administrators from Quantuma Advisory, a step intended to protect the interests of creditors while options for the business and its assets are assessed.
Trellus Health pursues asset sales
As part of the restructuring process, Trellus Health is seeking buyers for certain assets, including its US operating subsidiary, Trellus Health Inc.
However, the board expects that any transaction arising from the sale process will generate no return for existing shareholders. Creditors will therefore take priority as the company attempts to realise value from its remaining operations and intellectual property.
Trellus Health’s shares remain suspended from trading on AIM, with the company saying further announcements will be made as developments occur.
Administration threatens independent future
The decision represents a significant setback for Trellus Health’s strategy of building a standalone digital chronic care management business.
With available funding exhausted, the company’s technology, operating businesses and other assets are now more likely to be sold or separated through the restructuring process rather than developed under Trellus Health as an independent listed company.
Existing shareholders face the prospect of losing their entire investment, highlighting the financing and scaling challenges encountered by specialist digital healthcare companies seeking to commercialise technology-intensive care platforms.
Financial losses outweigh technical momentum
Trellus Health’s financial position has been characterised by substantial ongoing losses, negative free cash flow and declining shareholders’ equity, despite the company carrying no debt.
Technical indicators had provided a more positive signal, with the shares showing momentum above major moving averages before the suspension. However, the company’s loss-making financial position, lack of a dividend and impending administration substantially outweigh those technical factors.
More about Trellus Health plc
Trellus Health plc is a healthcare technology company focused on helping patients manage complex chronic conditions through digital tools and personalised resilience-based programmes.
Its Trellus Elevate platform combines data analytics, specialist coaching and individualised support, initially targeting gastrointestinal conditions such as inflammatory bowel disease. The platform is designed to improve patient self-management while reducing hospital admissions and emergency care utilisation.
The company also developed Trellus TrialSet, which provides pharmaceutical partners with support across clinical development and post-commercialisation patient engagement.
Founded by specialists from Mount Sinai with expertise in inflammatory bowel disease, Trellus Health joined AIM in May 2021 under the ticker TRLS. Its broader strategy has been to apply its resilience methodology and technology-enabled care model across multiple chronic conditions while demonstrating clinical benefits and potential cost savings for healthcare systems.
Leave a Reply